By Dennis Thompson HealthDay ReporterFRIDAY, Aug. 8, 2025 (HealthDay News) — More than 1 in 10 Americans have used a GLP-1 drug for weight loss, a new survey by the RAND research group reveals. About 12% say they’ve tried GLP-1 drugs, like Ozempic, Wegovy or Zepbound, with rates of use highest among people ages 50 to 64, survey results show.

Eli Lilly will seek regulatory approval for its next-generation weight-loss pill by year-end, based on data that suggests it may not be as potent as injectable GLP-1 drugs on the market.

In eagerly awaited results from a new study, the pharmaceutical company Eli Lilly reports that a pill its scientists developed causes people who are overweight or obese, but not diabetic, to lose significant amounts of weight.